CD274 and melanoma: At the time of anti-PD(L)1 initiation, the main tumor type was NSCLC (n = 537, 71%) followed by melanoma (n = 144, 19%) and urologic cancer (urothelial carcinoma or clear cell renal carcinoma) (n = 78, 10%).